Use of the Charlson combined comorbidity index to predict postradiotherapy quality of life for prostate cancer patients

International Journal of Radiation Oncology Biology Physics

Volumn 81, Issue 4, 2011, Pages 997-1004

  Wahlgren, Thomas ^a   Levitt, Seymour ^a,b   Kowalski, Jan ^c   Nilsson, Sten ^a   Brandberg, Yvonne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MINNESOTA   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Charlson score; Comorbidity; HDR brachytherapy; Health related quality of life; Localized prostate cancer

Indexed keywords

CHARLSON SCORE; COMORBIDITY; HDR BRACHYTHERAPY; HEALTH-RELATED QUALITY OF LIVES; LOCALIZED PROSTATE CANCER;

DISEASE CONTROL; HEALTH; ONCOLOGY; RADIOTHERAPY; REGRESSION ANALYSIS; SURVEYS; TUMORS;

DISEASES;

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ASSESSMENT TOOL; COGNITION; COMORBIDITY; DIABETES MELLITUS; EMOTION; EXTERNAL BEAM RADIOTHERAPY; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SOCIAL ASPECT;

AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; REGRESSION ANALYSIS;

EID: 80255134566     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.07.014     Document Type: Article

References (25)

1. M.S. Litwin, R.D. Hays, and A. Fink Quality-of-life outcomes in men treated for localized prostate cancer JAMA 273 1995 129 135
2. T.J. Wilt, R. MacDonald, and I. Rutks Systematic review: Comparative effectiveness and harms of treatments for clinically localized prostate cancer Ann Intern Med 148 2008 435 448 (Pubitemid 351665443)
3. M.E. Charlson, P. Pompei, and K.L. Ales A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 1987 373 383 (Pubitemid 17055592)
4. T.A. Hutchinson, D.C. Thomas, and B. MacGibbon Predicting survival in adults with end-stage renal disease: an age equivalence index Ann Intern Med 96 1982 417 423 (Pubitemid 12139862)
5. M. Charlson, T.P. Szatrowski, and J. Peterson Validation of a combined comorbidity index J Clin Epidemiol 47 1994 1245 1251 (Pubitemid 24361532)
6. G.R. Simon, M. Extermann, and A. Chiappori Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC) who are 70 years of age or older Cancer 112 2008 2021 2029 (Pubitemid 351574078)
7. N.H. Gordon, P. Silverman, and W. Lasheen Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer Breast Cancer Res Treat 102 2007 301 312 (Pubitemid 46474843)
8. S. Houterman, M.L. Janssen-Heijnen, and C.D. Verheij Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: An in-depth population-based study Prostate Cancer Prostatic Dis 9 2006 179 184 (Pubitemid 43970968)
9. P.C. Albertsen, J.A. Hanley, and J. Fine 20-year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095 2101 (Pubitemid 40617061)
10. A. Tewari, C.C. Johnson, and G. Divine Long-term survival probability in men with clinically localized prostate cancer: A case-control, propensity modeling study stratified by race, age, treatment and comorbidities J Urol 171 2004 1513 1519 (Pubitemid 38365408)
11. A.B. Chen, A.V. D'Amico, and B.A. Neville Patient and treatment factors associated with complications after prostate brachytherapy J Clin Oncol 24 2006 5298 5304 (Pubitemid 46631377)
12. P.I. Karakiewicz, N. Bhojani, and A. Neugut The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer J Sex Med 5 2008 919 927 (Pubitemid 351472202)
13. L.V. Van De Poll-Franse, L. Kwan, and R.E. Reiter The influence of cardiovascular disease on health related quality of life in men with prostate cancer: A 4-year followup study J Urol 179 2008 1362 1367
14. S.A. Arredondo, E.P. Elkin, and P.L. Marr Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: Data from CaPSURE Urology 67 2006 559 565 (Pubitemid 43343543)
15. J.J. Dapueto, L. Servente, and C. Francolino Determinants of quality of life in patients with cancer Cancer 103 2005 1072 1081 (Pubitemid 40270085)
16. T. Wahlgren, S. Nilsson, and B. Lennernas Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer Int J Radiat Oncol Biol Phys 69 2007 662 670 (Pubitemid 47418388)
17. T. Wahlgren, Y. Brandberg, and L. Haggarth Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: A prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25 Int J Radiat Oncol Biol Phys 60 2004 51 59 (Pubitemid 39165468)
18. A.W. Partin, M.W. Kattan, and E.N.P. Subong Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update JAMA 277 1997 1445 1451 (Pubitemid 27208886)
19. P. Narayan, G. Fournier, and V. Gajendran Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer Urology 44 1994 519 524
20. N.K. Aaronson, S. Ahmedzai, and B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376 (Pubitemid 23073154)
21. B. Bergman, M. Sullivan, and S. Sorenson Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and Comparison with the Sickness Impact Profile Acta Oncol 31 1992 19 28
22. P.M. Fayers Interpreting quality of life data: population-based reference data for the EORTC QLQ-C30 Eur J Cancer 37 2001 1331 1334 (Pubitemid 32588741)
23. S. Nilsson, B.J. Norlen, and A. Widmark A systematic overview of radiation therapy effects in prostate cancer Acta Oncol 43 2004 316 381 (Pubitemid 38887858)
24. S. Kumar, M. Shelley, and C. Harrison Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer Cochrane Database Syst Rev 2006 CD006019
25. G.D. Padula, M.J. Zelefsky, and E.S. Venkatraman Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 52 2002 439 443 (Pubitemid 34170848)